Jun 22, 2017 5:30am EDT Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)
May 17, 2017 8:30am EDT Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Issued Patent Coverage in Canada and Hong Kong
May 09, 2017 8:30am EDT Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma
Mar 22, 2017 8:30am EDT NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms
Mar 20, 2017 8:30am EDT Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)
Mar 03, 2017 8:30am EST NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development
Jun 16, 2016 8:00am EDT Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model
Jun 10, 2016 8:58am EDT Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.
